These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics. Chen XW; Sun YY; Fu L; Li JQ Eur J Med Chem; 2016 Nov; 123():332-353. PubMed ID: 27487565 [TBL] [Abstract][Full Text] [Related]
65. Studies towards the next generation of antidepressants. Part 4: derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor. Evrard DA; Zhou P; Yi SY; Zhou D; Smith DL; Sullivan KM; Hornby GA; Schechter LE; Andree TH; Mewshaw RE Bioorg Med Chem Lett; 2005 Feb; 15(4):911-4. PubMed ID: 15686885 [TBL] [Abstract][Full Text] [Related]
66. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145 [TBL] [Abstract][Full Text] [Related]
67. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930 [TBL] [Abstract][Full Text] [Related]
68. N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. Wakenhut F; Allan GA; Fish PV; Fray MJ; Harrison AC; McCoy R; Phillips SC; Ryckmans T; Stobie A; Westbrook D; Westbrook SL; Whitlock GA Bioorg Med Chem Lett; 2009 Sep; 19(17):5078-81. PubMed ID: 19647430 [TBL] [Abstract][Full Text] [Related]
69. Synthesis and preliminary screening of novel N-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}acetamides as potential atypical antipsychotic agents. Chandra Sekhar KV; Rao VS; Krishna MM J Enzyme Inhib Med Chem; 2009 Jun; 24(3):871-5. PubMed ID: 18825551 [TBL] [Abstract][Full Text] [Related]
71. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336 [TBL] [Abstract][Full Text] [Related]
72. Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents. Sekhar KV; Rao VS; Devambatla RKV; Kumar MM Bioorg Med Chem Lett; 2008 Dec; 18(23):6054-7. PubMed ID: 18948000 [TBL] [Abstract][Full Text] [Related]
73. Effects of a 5-HT7 receptor antagonist DR4004 on the exploratory behavior in a novel environment and on brain monoamine dynamics in mice. Takeda H; Tsuji M; Ikoshi H; Yamada T; Masuya J; Iimori M; Matsumiya T Eur J Pharmacol; 2005 Jul; 518(1):30-9. PubMed ID: 16002064 [TBL] [Abstract][Full Text] [Related]
74. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors. Asproni B; Pau A; Bitti M; Melosu M; Cerri R; Dazzi L; Seu E; Maciocco E; Sanna E; Busonero F; Talani G; Pusceddu L; Altomare C; Trapani G; Biggio G J Med Chem; 2002 Oct; 45(21):4655-68. PubMed ID: 12361392 [TBL] [Abstract][Full Text] [Related]
75. Synthesis and biological evaluation of 2-(4-fluorophenoxy)-2-phenyl-ethyl piperazines as serotonin-selective reuptake inhibitors with a potentially improved adverse reaction profile. Dorsey JM; Miranda MG; Cozzi NV; Pinney KG Bioorg Med Chem; 2004 Mar; 12(6):1483-91. PubMed ID: 15018922 [TBL] [Abstract][Full Text] [Related]